Assessment of inactivation procedures for SARS-CoV-2

Heidi Auerswald1, Sokhoun Yann1, Sokha Dul2, Saraden In1, Philippe Dussart1, Nicholas J. Martin3, Erik A. Karlsson1,* and Jose A. Garcia-Rivera2,*

Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), presents a challenge to laboratorians and healthcare workers around the world. Handling of biological samples from individuals infected with the SARS-CoV-2 virus requires strict biosafety measures. Within the laboratory, non-propagative work with samples containing the virus requires, at minimum, Biosafety Level-2 (BSL-2) techniques and facilities. Therefore, handling of SARS-CoV-2 samples remains a major concern in areas and conditions where biosafety for specimen handling is difficult to maintain, such as in rural laboratories or austere field testing sites. Inactivation through physical or chemical means can reduce the risk of handling live virus and increase testing ability especially in low-resource settings due to easier and faster sample processing. Herein we assess several chemical and physical inactivation techniques employed against SARS-CoV-2 isolates from Cambodia. This data demonstrates that all chemical (AVL, inactivating sample buffer and formaldehyde) and heat-treatment (56 and 98 °C) methods tested completely inactivated viral loads of up to 5 log10.

INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) has rapidly spread across the world. On 30 January 2020, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern and upgraded it to a pandemic on 11 March 2020 [1]. As of 20 August 2020, there have been over 22.2 million laboratory-confirmed cases and greater than 780,000 deaths reported globally [2]. Extensive testing is necessary to ensure accurate diagnosis, contact tracing and mitigate SARS-CoV-2 spread through isolation and quarantine procedures. Additionally, extensive testing facilitates the global public health response against COVID-19, providing critical information regarding the effectiveness of mitigation efforts.

Given the limited specific treatment options and the lack of an approved vaccine, SARS-CoV-2 isolates need to be handled according to strict biosafety measures [3, 4]. Extreme care in handling live samples prevents occupational exposure and requires extensive technical training and appropriate containment devices wearing recommended personal protective equipment (PPE). Therefore, the need for extensive testing in areas and conditions where biosafety for specimen handling is difficult to maintain remains a major concern. Indeed, scenarios still exist globally where there is need to sample outside of designated testing centres, conduct field investigations in difficult locales, transport non-secure samples, and, especially, testing being conducted in resource strained, underequipped and/or under-maintained laboratories. Inactivation through physical or chemical means reduces the risk from handling live samples and increases testing ability especially in low-resource settings due to easier and faster sample processing.

Cambodia is a tropical, resource poor, least developed country (LDC) in Southeast Asia with a large socio-economic dependence on tourism [5]. Cambodia is also a major hotspot of endemic and emerging infectious disease [6]. One particular, but not unique, issue faced in LDCs is the expansion of testing capacity due to a scarcity of testing laboratories, especially in remote provincial health centres. Therefore, SARS-CoV-2
samples from these rural health centres requires safe but rapid transportation to designated testing sites. Aside from active training and great care when handling live specimens from suspected cases, transportation of potentially infectious material requires increased protective equipment and packaging, often in reduced supply or of poor quality, even in the best of scenarios. Therefore, simple and effective inactivation of suspected samples that can be conducted onsite can greatly decrease risk of exposure during transportation, handling and testing, as well as reduce demand for protective equipment and supplies at a current global scarcity.

Herein, we evaluated the efficiency of various thermal and chemical inactivation methods on SARS-CoV-2 utilizing three separate SARS-CoV-2 isolates collected in Cambodia as part of the national surveillance and response to determine their effect on viral infectivity and RNA integrity tested via real-time reverse transcription polymerase chain reaction (RT-PCR).

METHODS

Ethics statement

All isolates were obtained as part of the first-line testing, analysis and preparedness of suspected cases through the national outbreak response. No primary clinical specimens or identifying information or any other individual-specific information was utilized in these studies or manuscript.

Cell lines

African green monkey kidney cells (Vero; ATCC CCL-81) were used for the isolation and culture of SARS-CoV-2 isolates. Vero E6 cells were used for the titration of infectious virus via TCID50. Both cell lines were cultivated in Dulbecco’s modified Eagle medium (DMEM; Sigma-Aldrich, Steinheim, Germany) supplemented with 10% foetal bovine serum (FBS; Gibco, Gaithersburg, MD, USA) and 100 µL/ml penicillin-streptomycin (Gibco) at 37°C and 5% CO2 atmosphere.

Virus culture and titration

Three SARS-CoV-2 isolates (designated hCoV-19/Cambodia/1775/2020, 1775; hCoV-19/Cambodia/18/2020, 2018; and, hCoV-19/Cambodia/2310/2020, 2310) were obtained and cultured in Vero cells. Upon infection with SARS-CoV-2 the culture medium was replaced by infection medium containing DMEM, 5% FBS, antibiotics, 2.5 µg ml⁻¹ Amphotericin B (Gibco) and 16 µg ml⁻¹ TPCK-trypsin (Gibco). Virus-containing supernatants, as determined by the presence of cytopathic effect (CPE), were harvested 6 days after infection by centrifugation at 1500 r.p.m. for 10 min. The concentration of viable virus was measured by TCID50 assay on Vero E6 cells in 96-well plates (TPP, Trasadingen, Switzerland) [7]. Briefly, serial dilutions of viral culture supernatant were inoculated onto cells using infection medium. After 4 days of incubation, plates were inactivated with 4% formaldehyde for 20 min then stained with 1% crystal violet solution in PBS for 20 min. Titré of viable virus was calculated applying the Spearman–Karber formula [8].

Inactivation of SARS-CoV-2 isolates

Inactivation was performed in triplicate using 140 µl aliquots of SARS-CoV-2 isolates (1775, 2018, and 2310; passage 3 from Vero cells). Chemical inactivation was performed following manufacturers’ recommendation and included: (i) adding 560 µl viral lysis buffer (AVL buffer including carrier RNA; AVL buffer) from the QI Amp Viral RNA Mini Kit (Qiagen, Hilden, Germany) for 10 min at room temperature according to the manufacturer’s recommendations; (ii) 200 µl inactivating sample buffer (GeneReach, Taichung City, Taiwan) containing 50% guanidinium thiocyanate (GITC) and 6% t-Octylphenoxypolyethoxyethanol (Triton X-100) for 15 min at room temperature; or (iii) 140 µl 4% Formaldehyde in PBS (General Drugs House, Bangkok, Thailand; end concentration 2%) for 15 min at room temperature. Thermal inactivation similarly performed on 140 µl aliquots of fresh virus culture: (iv) 56°C for 30 min; (v) 56°C for 60 min; and (vi) 98°C for 2 min in a thermo-block (Eppendorf, Hamburg, Germany). Sterile DMEM treated in the similar methods served as negative controls, and untreated SARS-CoV-2 isolates as positive controls. All samples and controls were handled in 1.5 ml PP reaction tubs (Greiner bio-one, Kremsmünster, Austria) during the treatment.

Analysis for viable virus post-inactivation

To determine if any viable virus remained post-inactivation, 50% Polyethylene glycol 8000 (Sigma-Aldrich, St. Louis, USA) in PBS was added (1/5 of total sample volume) to an aliquot from each sample condition and incubated overnight at 4°C. Following incubation, the virus was recovered by centrifugation at 1500 r.p.m. for 1 h. Precipitates were washed twice with sterile PBS, re-constituted with infection medium, and used for infecting the TCID50 on Vero E6 cells and recovery cultures on Vero cells. TCID50 and virus cultures plates were analysed for CPE 7 days post-inoculation (p.i.). Negative controls were treated the same way to examine cytotoxicity of possible remaining traces of inactivation solutions.

SARS-CoV-2 real-time RT-PCR

Following inactivation, RNA from one aliquot per condition per virus isolate and negative control was immediately extracted with the QIA Amp Viral RNA Mini Kit (Qiagen) and stored at −80°C until further processing. Real-time RT-PCR assays for SARS-CoV-2 RNA detection were performed in duplicate using the Charité Virologie algorithm (Berlin, Germany) to detect both E and RdRp genes [9]. In brief, real-time RT-PCR was performed using the SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase (Invitrogen) on the CFX96 Touch Real-Time PCR Detection System (BioRad, Hercules, CA, USA) ABI. Each 25 µl reaction mixture contained 5 µl of RNA, 3.1 µl of RNase-free water, 12.5 µl of 2X PCR buffer, 1 µl of SuperScriptTM III RT/Platinum Taq Mix, 0.5 µl of each 10 µM forward and reverse primer, and 0.25 µl of probe (E_Sarbeco_P1 or RdRP_SARSr-P2) using the following thermal cycling conditions; 10 min at 55°C for reverse transcription, 3 min at 94°C for PCR initial activation, and 45 cycles of 15 s at 94°C and 30 s at 58°C.

AUERSWALD ET AL. JOURNAL OF GENERAL VIROLOGY 2021;102:001539
Table 1. SARS-CoV-2 isolates used for inactivation

| SARS-CoV-2 isolate | Before treatment TCID$_{50}$ ml$^{-1}$ | After PEG precipitation (positive control) TCID$_{50}$ ml$^{-1}$ | Post inactivation (all methods) TCID$_{50}$ ml$^{-1}$ |
|--------------------|----------------------------------------|--------------------------------------------------------------|---------------------------------------------------|
| 1775               | 2.11E+05                               | 4.10E+04                                                    | Not detected                                     |
| 2018               | 1.19E+04                               | 6.09E+03                                                    | Not detected                                     |
| 2310               | 6.67E+05                               | 1.22E+05                                                    | Not detected                                     |

Statistical analysis

Statistics were performed using GraphPad Prism for Windows, version 7.02 (GraphPad Software, La Jolla, CA, USA). Analysis of variance was performed comparing mean Ct values for each inactivation method. Difference between standard (AVL) and each specific inactivation method was determined using Dunnett’s test for many-to-one comparison. A P-value of less than 0.05 was considered to indicate statistical significance. Agreement, including bias and 95% confidence interval, between Ct values following inactivation by AVL and other methods was assessed using a method described by Bland and Altman [10]. The mean Ct value of AVL and the other inactivation method assessed was plotted on the X-axis. The difference between the two values was plotted on the Y-axis. Cut-off values of 2 and −2 are plotted.

RESULTS

Inactivation efficiency

All chemical and thermal inactivation methods resulted in the reduction of viable SARS-CoV-2 to undetectable levels. Untreated virus isolates had a concentration of viable virus up to 6.67×10$^5$ (isolate 2310) before treatment (Table 1). Therefore, the reduction of viable virus across inactivation levels was at least 5 log$_{10}$. Precipitation of virus and complete removal of inactivation solution before infecting Vero E6 cells for TCID$_{50}$ titration ensured that cell death was not induced by chemical products used in the inactivation procedure. Successful recovery of virus post-PEG precipitation was determined by RT-PCR on the same samples used for TCID$_{50}$.

All attempts to recover viable virus post-inactivation on Vero cells were unsuccessful up to day 6 p.i.

Effect of inactivation procedure on RT-PCR

As all samples were incubated with AVL buffer, this condition serves as the standard for the comparison of the diverse inactivation methods. There were significant differences between the Ct values for the RdRp (ANOVA; P<0.0001) and E (ANOVA; P<0.0001) genes. Following many-to-one comparison of AVL to all other forms of inactivation used in this study (Fig. 1), only formaldehyde inactivation was significantly different for the RdRp (Dunnet’s test; P=0.0016) and E (Dunnet’s test; P=0.0007) genes. In order to demonstrate the agreement in Ct values for the inactivation methods compared to the standard AVL, Bland–Altman plots were compared. Samples inactivated by formaldehyde were the only ones where the absolute bias Ct value for all samples was greater than two compared to AVL for RdRp (−20.32±1.75) and E (−19.80±1.17) genes. All other inactivation methods resulted in absolute bias Ct values of less than one except for the RdRp gene following inactivation at 56°C for 30 min (−1.15±1.08), though this was still within the limits of agreement.

DISCUSSION

Following the rapid global spread of SARS-CoV-2 and the need for universal testing, more and more individuals are exposed to live virus samples, thereby increasing the chances of occupational infection. The WHO and United States Centers for Disease Control (US CDC) have released laboratory guidelines to mitigate risk of exposure during diagnostic and research procedures [3, 4]. Despite recommendations for handling within contained biosafety cabinets,

![Fig. 1. Comparison of Ct values of SARS-CoV-2 (a) E gene and (b) RdRp gene for three isolates (1775; circles, 2018; squares, 2310; triangles) inactivated by different methods. Inactivation with 2% formaldehyde for 15 min at room temperature results in significantly elevated Ct values for both genes (***P<0.0001, one-way ANOVA comparison to AVL inactivation).](image-url)
individuals working with these samples are still required to handle potentially live virus at the initial steps of acquiring and preparing the suspected samples prior testing, thereby increasing the risk of exposure. Potential exposure greatly increases in situations requiring large numbers of samples to be processed under harsh conditions, in underequipped or poorly maintained laboratories, and even within the sample transportation system, such as found in developing or rural areas of the world. Therefore, the continued need for COVID-19 testing worldwide requires utilization of simple and effective inactivation techniques.

Previous studies have been conducted on the effectiveness of chemical inactivation techniques on SARS-CoV-2 [11–16], the majority of these based on the experiences with infectious agents of concern such as Ebola [17] and SARS and MERS coronaviruses [18]. As with other viruses, the primary step in the molecular detection of SARS-CoV-2 is viral lysis to begin the extraction of nucleic acids. The buffers used in this lysis step yield varying results [11, 13, 16, 17, 19, 20]; however, the study by Pastorino et al. [11] found that AVL buffer alone was successfully able to fully inactivate up to $4\textendash5\log_{10}$ of virus from three different primary isolates of SARS-CoV-2. Other studies using higher vial litres in their inactivation experiments [11, 13, 16] observed only incomplete inactivation with AVL buffer alone nevertheless confirming the $5\textendash6\log_{10}$ decrease of infectivity. Apart from differences in isolates utilized and a slight reduction in titre, it is unclear as to the reasons why AVL buffer fully inactivated in this study versus others, but further work is warranted to determine the exact effectiveness of this step alone. Moreover, the impact of the inactivation method on various clinical specimen should be investigated as we utilized virus stock for this study, and the complex composition of clinical samples might influence the efficacy of inactivation as well as virus detection.

Inactivating sample transport media, either made in-house or commercially available, also presents an attractive way to inactivate samples at the point of sampling to ensure safe handling along the transport chain and within the laboratory. These inactivating transport media include the key components of many viral lysis buffers including chaotropic agents (GITC), detergents (Triton X-100) and buffering agents (EDTA, Tris-HCL) to inactivate a preserve viral RNA. Previous studies have shown that GITC-lysis buffers like AVL are able to inactivate SARS-CoV-2 samples [11–13, 16]; however, the addition of Triton-X may be necessary for complete inactivation [11, 16]. In line with these studies, commercial sample transport media containing both GITC and GITC/Triton-X buffers were successfully able to inactivate up to $5\log_{10}$ of virus with no loss of molecular diagnostic sensitivity.

Apart from sample media and buffers utilized for diagnostic testing, various disinfectant and inactivating chemicals are available for sample treatment. Formaldehyde has a long history of use for inactivation against a number of viruses and in a number of fixation techniques, including vaccine preparations [21, 22]. Formaldehyde has been shown to successfully inactivate both SARS and MERS [18, 23, 24] and has been suggested to be a viable alternative for disinfection and inactivation of SARS-CoV-2 [13–15, 23, 24]. Formaldehyde treatment (end concentration 2%, 15 min at room temperature) did successfully inactivate up to $5\log_{10}$ of virus; however, this treatment severely impacted viral detection in subsequent molecular testing. This decreased detection is not unexpected as formaldehyde treatment results in RNA degradation and modification [25]. Therefore, formaldehyde treatment does not appear to be a solution for increased molecular SARS-CoV-2 testing; however, it does remain a viable alternative for sample inactivation or disinfection.

Perhaps the most studied technique thus far regarding SARS-CoV-2 has been thermal inactivation at various times and temperatures [11, 14, 16, 26–29]. Several previous studies have shown heat to be an effective inactivation technique against other coronaviruses, including SARS, MERS and human seasonal strains [18, 27, 30]. Similar to previous studies, $56^\circ C$ heat treatment for 30 or 60 min was fully able to inactivate up to $5\log_{10}$ of SARS-CoV-2 from three different isolates [11, 15, 16, 26, 31, 32]. Interestingly, while other studies utilized $95^\circ C$ for 5 to 10 min for inactivation, heat treatment at $98^\circ C$ for only 2 min was also able to completely inactivate up to $5\log_{10}$ of virus. These results are very promising as high heat treatment is extremely rapid and may be a vital addition to the testing arsenal, as RT-PCR can possibly be performed directly from these samples without the need for nucleic acid extraction [33, 34]. It has to be considered, that we used small volumes (140 µl) of virus culture samples and inactivation of larger volumes and clinical specimen might be more difficult. It was already shown that heat-inactivation decreases the sensitivity for N and ORF gene RT-PCRs in throat swab samples with low viral load [35, 36] and nasopharyngeal swabs [37]. Interestingly, the shortened time period of high heat treatment may mitigate some of the reduction in detection seen in previous studies and make this technique more employable [11, 16]. This high heat treatment might be also favourable as specimen with high vial load (6 log$_{10}$ TCID) remain infectious even after treatment at $56^\circ C$ for 30 min and $60^\circ C$ for 60 min [16].

Overall, the agreement and retained sensitivity amongst RT-PCR results, combined with the fact that all methods resulted in 100% virus inactivation up to a viral load of $5\log_{10}$ suggests that any of the tested methods, except formaldehyde, are useful to inactivate SARS-CoV-2 samples. Given the WHO recommendation to ‘test, test, test’, these data can help to optimize sample inactivation for austere or remote areas. Indeed, it may be possible to use basic tools such as a stopwatch and boiling water to achieve 100% virus inactivation without compromising sample integrity, significantly decreasing possible exposure during sample transportation and handling, allowing for dissemination of testing to labs with decreased biosafety capacity, and possibly reducing the global demand for a dwindling supply of PPE.

Funding information

This work, including that of Dr Auerswald, was supported, in part, by internal funding through Institut Pasteur in Cambodia. Dr Karlsson is supported, in part, by the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (Grant No. 1 IDSEP190051-01-00) and through internal funding at Institut Pasteur in Cambodia. The findings and conclusions...
in this report are those of the authors and do not necessarily represent the official views of the US Department of Health and Human Services. This work was also partially funded and supported by the Armed Forces Health Surveillance, Branch Global Emerging Infections Surveillance Section.

Acknowledgements

We would like to acknowledge the patients, Cambodian Ministry of Health and Cambodian Center for Disease Control, Rapid Response Team members, and the doctors, nurses, and staff of the reference hospitals in Cambodia for their response to the COVID-19 pandemic. We thank all of the technicians and staff at Institut Pasteur du Cambodge in the Virology Unit and at NAMRU-2 in the Molecular Unit involved in this work.

Conflicts of interest

The authors declare that there are no conflicts of interest.

References

1. World Health Organization. 2020. Coronavirus disease (COVID-19) outbreak. https://www.who.int/westernpacific/emergencies/covid-19 [accessed May 13th 2020].
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020;20:533–534.
3. United States Centers for Disease Control and Prevention. Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19) 2020.
4. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance. 2 March 2020.
5. United Nations. Un list of least developed countries 2019.
6. Burgos S, Ear S. Emerging infectious diseases and public health policy: insights from Cambodia, Hong Kong and Indonesia. Transbound Emerg Dis 2015;62:96–101.
7. Flint SJE W, Racaniello VR, Skalka AM. Virological Methods. Principles of Virology. ASM Press; 2009.
8. Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol 2016;5:85–86.
9. Corman VM, Landi D, Kaiser M, Molenkamp R, Meijer A et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 2020;25:2000045.
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–310.
11. Pastorino B, Touret F, Gilles M, Lamballerie X, Charrel RN. Evaluation of heating and chemical protocols for inactivating SARS-CoV-2. bioRxiv 2020.
12. Scallan MF, Dempsey C, MacSharry J, O’Callaghan I, O’Connor PM. Validation of a lysis buffer containing 4 M guanidinium thiocyanate (GITC)/ Triton X-100 for extraction of SARS-CoV-2 RNA for COVID-19 testing: comparison of formulated lysis buffers containing 4 to 6 M GITC. arXiv 2020.
13. Welch SR, Davies KA, Buczkowski H, Hettiarachchi N, Green N et al. Analysis of inactivation of SARS-CoV-2 by specimen transport media, nucleic acid extraction reagents, detergents, and fixatives. J Clin Microbiol 2020;58:e01713–e01720.
14. Patterson EL, Prince T, Anderson ER, Casas-Sanchez A, Smith SL et al. Methods of inactivation of SARS-CoV-2 for downstream biological assays. J Infect Dis 2020;222:1462–1467.
15. Jureka AS, Silvas JA, Basler CF. Propagation, inactivation, and safety testing of SARS-CoV-2. Viruses 2020;12:622.
16. Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel RN. Heat inactivation of different types of SARS-CoV-2 samples: what protocols for biosafety, molecular detection and serological diagnostics? Viruses 2020;12:735.
17. Smither SJ, Wellar SA, Phelps A, Eastaugh L, Ngugi S et al. Buffer AVL alone does not inactivate Ebola virus in a representative clinical sample type. J Clin Microbiol 2015;53:3148–3154.
18. Darnell MER, Subbarao K, Feinstone SM, Taylor DR. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods 2004;121:85–91.
19. Blow JA, Dohm DJ, Negley DL, Morens CM. Virus inactivation by nucleic acid extraction reagents. J Virol Methods 2004;119:195–198.
20. Ngo KA, Jones SA, Church TM, Fuschino ME, George KS et al. Unreliable inactivation of viruses by commonly used lysis buffers. Applied Biosafety 2017;22:56–59.
21. Sabbaghi A, Miri SM, Keshavarz M, Zargar M, Ghaemi A. Inactivation methods for whole influenza vaccine production. Rev Med Virol 2019;29:e2074.
22. Salk JE, Krech U, Youngner JS, Bennett BL, Lewis LJ et al. Formaldehyde treatment and safety testing of experimental poliovirus vaccines. Am J Public Health Nations Health 1954;44:563–570.
23. Henwood AF. Coronavirus disinfection in histopathology. J Histochem 2020;43:102–104.
24. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104:246–251.
25. Evers DL, Fowler CB, Cunningham BR, Mason JT, O’Leary TJ. The effect of formaldehyde fixation on RNA: optimization of formaldehyde adduct removal. J Mol Diagn 2011;13:282–288.
26. Batéjat C, Grassin Q, Manuguerra J-C, Leclercq I. Heat inactivation of the severe acute respiratory syndrome coronavirus 2. bioRxiv 2020.
27. Kampf G, Voss A, Scheithauer S. Inactivation of coronaviruses by heat. J Hosp Infect 2020;105:348–349.
28. Lista M, Page R, Sertiya H, Matos P, Ortiz-Zapater E. Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation 2020.
29. Peré H, Podglajen I, Baillard J-L, Mboumba Bouassa R-S, Veyer D et al. Thermal inactivation and nucleic acid amplification-based testing for SARS-CoV-2. J Clin Virol 2020;131:104588.
30. Leclercq I, Batéjat C, Burguérié AM, Manuguerra J-C. Heat inactivation of the middle East respiratory syndrome coronavirus. Influenza Other Respir Viruses 2014;8:585–586.
31. Wu Z-G, Zheng H-Y, Gu J, Li F, Lv R-L, Z-g W, H-y Z, R-I L et al. Effects of different temperature and time durations of virus inactivation on results of real-time fluorescence PCR testing of COVID-19 viruses. Curr Med Sci 2020;40:614–617.
32. Wang Y, Song W, Zhao Z, Chen P, Liu J et al. The impacts of viral inactivating methods on quantitative RT-PCR for COVID-19. Virus Res 2020;285:197988.
33. Grant PR, Turner MA, Shin GY, Nastouli E, Levett LJ. Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic. bioRxiv 2020.
34. Fomsgaard AS, Rosenstienere MW. An alternative workflow for molecular detection of SARS-CoV-2 - escape from the NA extraction kit-shortage. Copenhagen, Denmark, March 2020. Euro Surveill 2020;25.
35. Pan Y, Long L, Zhang D, Yuan T, Cui S et al. Potential false-negative nucleic acid testing results for severe acute respiratory syndrome coronavirus 2 from thermal inactivation of samples with low viral loads. Clin Chem 2020;66:794–801.
36. Zou J, Zhi S, Chen M, Su X, Kang L et al. Heat inactivation decreases the qualitative real-time RT-PCR detection rates of clinical samples with high cycle threshold values in COVID-19. Diagn Microbiol Infect Dis 2020;98:115109.
37. Chen H, Wu R, Xing Y, Du Q, Xue Z et al. Influence of different inactivation methods on severe acute respiratory syndrome coronavirus 2 RNA copy number. J Clin Microbiol 2020;58:e00958–e00920.